Anti-proliferative effect of LXR agonist T0901317 in ovarian carcinoma cells

Ovarian cancer is the most common cause of cancer related death from gynecologic tumors in the United States. The insidious nature of the disease precludes early diagnosis, therefore surgical debulking and chemotherapy are considered as standard treatment modalities for advanced stages. We investiga...

Full description

Saved in:
Bibliographic Details
Published in:Journal of ovarian research 2010-05, Vol.3 (1), p.13-13, Article 13
Main Authors: Rough, James J, Monroy, M Alexandra, Yerrum, Smitha, Daly, John M
Format: Article
Language:English
Subjects:
Agonists (Biochemistry)
Cancer
Cell cycle
Cell proliferation
Chemotherapy
Composition
Drug therapy
Health aspects
Liver
Ovarian cancer
Prevention
Proteins
Transcription factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian cancer is the most common cause of cancer related death from gynecologic tumors in the United States. The insidious nature of the disease precludes early diagnosis, therefore surgical debulking and chemotherapy are considered as standard treatment modalities for advanced stages. We investigated the effect of the LXR agonist, T0901317, on ovarian cancer cell proliferation and apoptosis as a potential therapeutic agent. T0901317 treatment resulted in a significant (P
ISSN:1757-2215
1757-2215
DOI:10.1186/1757-2215-3-13